BeiGene’s Brukinsa Set To Take On Imbruvica With CLL Approval

The BTK inhibitor demonstrated superiority to AbbVie/J&J’s Imbruvica for overall response in relapsed/refractory CLL, in addition to hitting a progression-free survival endpoint versus chemotherapy in the first-line.

BeiGene's Brukinsa adds US indication for chronic lymphocytic leukemia • Source: Shutterstock

With US approval to treat first-line and relapsed/refractory chronic lymphocytic leukemia, BeiGene, Ltd.’s Brukinsa appears well positioned to compete with AbbVie Inc./Johnson & Johnson’s established BTK inhibitor Imbruvica (ibrutinib). Multiple market analysts predicted significant revenue growth for Brukinsa with this latest approval in the largest leukemia setting.

BeiGene announced US Food and Drug Administration approval for Brukinsa (zanubrutinib) late on 19 January in CLL and small lymphocytic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip